Umdlavuza wepancreatic: ukuxilongwa
Uma udokotela esola ukuthi othile unomdlavuza we-pancreatic, uzoqala abuze umlando wesiguli, umlando wezokwelapha emndenini, bese ebheka izimpawu zesifo. Lezi zivivinyo ezilandelayo zingasetshenziswa ukuthola umdlavuza we-pancreatic.
Ukuhlolwa okujwayelekile
I-1. Ukuhlolwa ngokomzimba
Udokotela uzohlola isikhumba sakho namehlo akho ukuthi aphuzi yini, okuwuphawu lwe-jaundice.
Ukuqoqeka okungavamile kuketshezi esiswini, okubizwa ngokuthi ama-ascites, kungaba esinye isibonakaliso somdlavuza.
2. Ukuhlolwa kwegazi
Odokotela bangathatha amasampula egazi ukuhlola amazinga angajwayelekile we-bilirubin nezinye izinto.
I-CA19-9 iyimpawu yokumila. I-CA19-9 ivame ukuphakama ezigulini ezinomdlavuza we-pancreatic, kepha i-CA 19-9 akufanele isetshenziswe njengenkomba yokutholakala komdlavuza we-pancreatic, ngoba izinga eliphakeme le-CA 19-9 lingabuye libe uphawu lwezinye izifo. Izibonelo zifaka i-pancreatitis, i-cirrhosis yesibindi nokuvinjelwa komgudu ovamile we-bile.
3. Ukuhlolwa kwesithombe
Ukuhlolwa kwe-imaging kusiza udokotela ukuthola ukuthi umdlavuza ukuphi nokuthi ususabalele yini kusukela kumanyikwe kuya kwezinye izingxenye zomzimba.
Computer tomography (CT or CAT) scan.
Positron emission tomography (PET) scan or PET-CT scan.
ultrasound
I-Endoscopic Ultrasound (EUS)
I-endoscopic retrograde ye-cholangiopancreatographyography (ERCP)
I-Percutaneous transhepatic cholangiography (PTC)
Ukuhlolwa kwe-biopsy kanye nezicubu
I-fine inaliti aspiration (FNA), kusetshenziswa izinaliti ezinhle ezifakwe kuma-pancreas ukufisa amangqamuzana.
4. Ukutholwa kwamangqamuzana kwesimila
Udokotela wakho angancoma ukuhlolwa kwelabhorathri kuma-tumor noma amasampuli egazi ukuthola ama-biomarker ahlukahlukene. Ama-biomarkers angamaprotheni nezakhi zofuzo eziqondene nomdlavuza othile, futhi imiphumela yalezi zivivinyo ingasiza ekuqondiseni izinqumo zokwelashwa.
Umdlavuza wepancreatic: isiteji
Indlela ejwayelekile yokubeka umdlavuza wepancreatic ukuwuhlukanisa ngezigaba ezi-4: ngokuya ngokuthi ingasuswa yini ngokuhlinzwa nokuthi isatshalaliswa kuphi
Umdlavuza we-pancreatic obonakalayo
Lo mdlavuza we-pancreatic ungasuswa ngokuhlinzwa. Isimila singatholakala kuphela kumanyikwe noma sinwebeke ngaphandle kwaso, kepha asikakhuli sibe umthambo obalulekile noma umthambo kule ndawo. Abukho ubufakazi bokuthi isimila sisabalale ngaphezu kwamanyikwe. Cishe i-10% kuya ku-15% yeziguli ezikulesi sigaba lapho zitholakala khona.
Umdlavuza we-pancreatic ongasetshenziswa emngceleni
Tumors that may be difficult or impossible to surgically remove at first diagnosis, but after chemotherapy and / or radiation therapy, the tumor can be reduced first, then the tumor can be surgically removed later, marginal cancer cells are negative, marginal negative means no visible Cancer cells are left behind.
Umdlavuza we-pancreatic osendaweni
Lolu hlobo lwesilonda lusatholakala endaweni ezungeze amanyikwe, kepha ngenxa yokuthi selukhule lwaba umthambo oseduze noma umthambo noma isitho esiseduze, ngeke lususwe ngokuhlinzwa. Kodwa-ke, akukho okubonisa ukuthi ihambele kunoma yiliphi ibanga emzimbeni. Cishe ama-35% kuye kuma-40% eziguli akulesi sigaba ngesikhathi sokuxilongwa.
Umdlavuza we-pancreatic we-metastatic
Isimila sisabalale ngaphezu kwamanyikwe, njengesibindi noma ingxenye ekude yesisu. Cishe ama-45% kuye kuma-55% eziguli akulesi sigaba lapho zitholakala khona.
Isiteji se-TNM
Odokotela bavame ukusebenzisa uhlelo lwe-TNM ukwenza iziguli ezinomdlavuza we-pancreatic ezingahlinzwa. Iziguli eziningi ezinomdlavuza we-pancreatic azikwazi ukuhlinzwa. Ngakho-ke, uhlelo lwe-TNM alusebenzi kuwo wonke umdlavuza we-pancreatic njengamanye umdlavuza.
Isigaba 0: sisho i-carcinoma in situ, umdlavuza awukakhuli epayipini (Tis, N0, M0).
Isigaba IA: Isigaxa se-pancreatic siyi-2 cm noma sincane futhi asisakazekanga kuma-lymph node noma kwezinye izingxenye zomzimba (T1, N0, M0).
Isigaba IB: Isigaxa se-pancreatic sikhulu kuno-2 cm futhi asisakazekanga kuma-lymph node noma kwezinye izingxenye zomzimba (T2, N0, M0).
Isigaba IIA: Isimila singaphezu kwamanyikwe, kepha isimila asisakazekanga emithanjeni noma emithanjeni eseduze, futhi asisakazekanga kunoma yiziphi izakhi noma ezinye izingxenye zomzimba (T3, N0, M0).
Isigaba IIB: Isigaxa sanoma iluphi usayizi olungakasakazeki emithanjeni noma emithanjeni eseduze, kepha selusabalele kuma-lymph node futhi alusakazelanga kwezinye izingxenye zomzimba (T1, T2 noma T3; N1; M0)
Isigaba III: Isimila sisabalalele emithanjeni eseduze, emithanjeni, kanye / noma kuma-lymph node, kepha asisakazekanga kwezinye izingxenye zomzimba (T4, N1, M0).
Isigaba IV: Noma yisiphi isimila esisabalalele kwezinye izingxenye zomzimba (noma iyiphi i-T, noma iyiphi i-N, M1).
Ukubuyela emuva: Umdlavuza obuyile umdlavuza oseluleme ngemuva kokwelashwa. Uma umdlavuza ubuya, kuzoba nomunye umzuliswano wokuhlolwa ukuqonda ubukhulu bokuphindeka. Lokhu kuhlolwa kanye nokuskena kuvame ukufana nalokho okwenziwa ngesikhathi kutholakala ukuxilongwa kwasekuqaleni.
Umdlavuza wepancreatic: izinketho zokwelashwa
Izinketho zokwelashwa ezivame kakhulu zomdlavuza we-pancreatic zibalwe ngezansi. Izinketho zokwelashwa zamanje zomdlavuza wepancreatic ukuhlinzwa, ukwelashwa ngemisebe, i-chemotherapy, kanye nokwelashwa okuqondisiwe. Izinketho zokwelashwa nezincomo kuncike ezicini eziningana, kufaka phakathi uhlobo nesigaba somdlavuza, imiphumela emibi engaba khona, kanye nokuthandwa yisiguli nempilo yonke.
Lapho kutholakala umdlavuza wokuqala we-pancreatic, kukhuphuka izinga lokuphulukisa eliphumelelayo. Kodwa-ke, ukwelashwa okusebenzayo kungasiza ekulawuleni izifo zeziguli ezinomdlavuza osezingeni eliphakeme we-pancreatic ukuzisiza ziphile isikhathi eside.
Ukuhlinzwa komdlavuza we-Pancreatic
Surgeons remove all or part of the pancreas according to the location and size of the pancreatic tumor, and the area of healthy tissue surrounding the tumor is often removed. The purpose of the operation is to have a “clean edge”, which means to go to the edge of the operation, except for healthy tissue, there are no cancer cells.
Ngeshwa, kuphela iziguli ezingama-20% ezinomdlavuza we-pancreatic ezingakwazi ukuhlinzwa ngoba umdlavuza omkhulu we-pancreatic usuvele ususetshenzisiwe ngesikhathi sokuxilongwa. Uma ukuhlinzwa kungeyona into yokuqala ongakhetha ngayo, wena nodokotela wakho nizokhuluma ngezinye izindlela zokwelashwa.
Pancreatic cancer surgery can be used in combination with radiation therapy and / or chemotherapy. Radiation therapy and chemotherapy are usually given after surgery and are called adjuvant therapy. Chemotherapy and radiotherapy given before surgery to shrink the tumor are called neoadjuvant therapy. If these treatments are given before surgery, the tumor usually needs to be restaged before surgery.
Odokotela abahlinzayo bangenza izinhlobo ezahlukahlukene zokuhlinzwa ngokuya ngenhloso yokuhlinzwa:
I-Laparoscopy
Udokotela ohlinzayo angakhetha ukuqala nge-laparoscope ukubona ukuthi umdlavuza ususabalele nakwezinye izingxenye zesisu. Uma isivele isetshenzisiwe, ukususwa kokuhlinzwa kwesimila esiyinhloko ngokuvamile akunconywa.
Ukususwa kokuhlinzwa kwesimila se-pancreatic
Indlela yokuhlinzwa incike ekutheni isimila sitholakala kuphi kumanyikwe, futhi ama-lymph node aseduze asuswa njengengxenye yokuhlinzwa.
Uma umdlavuza usekhanda lamanyikwe kuphela, udokotela ohlinzayo angenza i-Whipple operation, okuwukuhlinzwa okubanzi lapho udokotela ohlinzayo asusa khona ikhanda namathumbu amancane, ingxenye yomgudu wenyongo nesisu samanyikwe, abese exhuma kabusha umgudu wokugaya ukudla nohlelo lwe-bile duct.
Uma umdlavuza ungumsila wamanyikwe, ukusebenza okuvamile yi-distal pancreatectomy. Kulokhu kusebenza, udokotela ohlinzayo ususa umsila wamanyikwe, umzimba wamanyikwe, nobende.
Uma umdlavuza usakazeka kumanyikwe, noma utholakala ezindaweni eziningi zamanyikwe, kungadingeka i-pancreatectomy ephelele. I-Pancreatectomy ukususwa kwawo wonke amanyikwe, ingxenye yamathumbu amancane, ingxenye yesisu, umgudu ovamile we-bile, i-gallbladder ne-spleen.
Ngemuva kokuhlinzwa, isiguli sidinga ukuhlala esibhedlela izinsuku ezimbalwa futhi singadinga ukuphumula ekhaya isikhathi esingangenyanga. Imiphumela emibi yokuhlinzwa ifaka ukukhathala nobuhlungu ezinsukwini ezimbalwa zokuqala ngemuva kokuhlinzwa. Eminye imiphumela emibi ebangelwe yi-
removal of the pancreas include indigestion and diabetes.
Ukwelashwa ngemisebe kumdlavuza we-pancreatic
Radiation therapy uses high-energy x-rays or other particles to destroy cancer cells. The most common type of radiation therapy is called external radiation therapy, which is radiation given from a machine outside the body.
Ukwelashwa kwemisebe yangaphandle wuhlobo olusetshenziswa kakhulu ukwelashwa ngemisebe yomdlavuza wepancreatic. Izinhlelo zokwelashwa ngemisebe (amapulani) zivame ukunikezwa ngenombolo ethile yezokwelapha isikhathi esithile.
Kunezindlela ezahlukahlukene zokwelashwa ngemisebe:
Ukwelashwa kwemisebe yendabuko kubizwa nangokuthi ukwelashwa ngemisebe okuvamile noma okujwayelekile. Inikezwa umthamo ophansi wokwelashwa ngemisebe nsuku zonke amasonto ama-5 kuye kwayisithupha.
I-Stereotactic radiotherapy (SBRT) noma i-Cyber ummese
I-Stereotactic radiotherapy (SBRT) noma i-Cyber ummese inganikezwa umthamo ophakeme wokwelashwa nsuku zonke isikhathi esifushane, imvamisa cishe izinsuku ezi-5. Lolu wuhlobo olusha kakhulu lokwelashwa ngemisebe olunganikeza ukwelashwa ngezilonda okwenziwe endaweni futhi kudinga ukwelashwa okumbalwa. Kusezikhungweni ezikhethekile ze-radiotherapy ezinolwazi nobuchwepheshe lapho le ndlela ingasetshenziswa ukwelapha umdlavuza we-pancreatic.
I-Chemotherapy kumdlavuza we-pancreatic
I-Chemotherapy ivame ukunikezwa ngasikhathi sinye njengokwelashwa ngemisebe ngoba ingakhuphula umphumela wokwelashwa ngemisebe, okubizwa ngokuthi ukuzwela ngemisebe. Ukusetshenziswa okuhlangene kwe-chemotherapy ne-radiotherapy kunganciphisa isimila futhi kusize udokotela asuse isimila futhi ngokuhlinzwa. Kodwa-ke, uma isetshenziswa kanyekanye nokwelashwa ngemisebe, umthamo we-chemotherapy uvame ukuba phansi kunowekhemotherapy kuphela.
Ukwelashwa ngemisebe kungasiza ekunciphiseni ukubakhona komdlavuza we-pancreatic noma ukuphinda ukhule, kepha kusekhona ukungaqiniseki okuningi ngokuthi kungasandisa yini isiguli.
Imiphumela emibi yokwelashwa ngemisebe ingafaka ukukhathala, ukusabela okuncane kwesikhumba, isicanucanu, ukucasuka kwesisu nohudo. Ngemuva kokwelashwa, imiphumela emibi eminingi izonyamalala.
Ukwelashwa ngamakhemikhali
I-Chemotherapy isebenzisa izidakamizwa ukuqeda amangqamuzana omdlavuza ngokuvimbela amandla awo okukhula nokuhlukanisa.
Iziguli zingathola umuthi owodwa noma inhlanganisela yezidakamizwa ezahlukahlukene ngasikhathi sinye. Okulandelayo yimithi evunyelwe yi-US Food and Drug Administration (FDA) yomdlavuza we-pancreatic:
I-Capecitabine (Xeloda)
I-Erlotinib (Tarceva)
I-Fluorouracil (5-FU)
I-Gemcitabine (Gemzar)
I-Irinotecan (Camptosar)
Folic acid (Wellcovorin)
I-Paclitaxel (Abraxane)
I-Nanoliposome irinotecan (i-Onivyde)
I-Oxaliplatin (Eloxatin)
Lapho ukusetshenziswa kwezidakamizwa ezimbili noma ngaphezulu ndawonye, imvamisa kuba nemiphumela emibi eminingi. Ukwelashwa kokuhlanganiswa kwezidakamizwa kuvame kakhulu ezigulini ezinesimo esihle somzimba futhi kungazinakekela.
Yikuphi ukuhlanganiswa kwezidakamizwa okufanele kusetshenziswe kuncike esikhungweni somdlavuza, ikakhulukazi isipiliyoni se-oncologist ngomuthi, kanye nemiphumela engemihle ehlukile kanye nempilo ephelele yesiguli. I-chemotherapy yomdlavuza wepancreatic ihlukaniswe ngezinhlobo ezilandelayo ngokwesikhathi:
Ukwelashwa ngamakhemikhali kokuqala
Lokhu kuvame ukubhekisa ekwelashweni kokuqala kweziguli ezinomdlavuza we-pancreatic wakuleli osethuthukile noma we-metastatic.
Ukwelashwa ngamakhemikhali kolayini wesibili
Lapho ukwelashwa kolayini wokuqala kungasebenzi noma ukumelana nomuthi kungakwazi ukulawula ukukhula komdlavuza, umdlavuza ubizwa ngokuthi ngumdlavuza ophikisayo. Ukwelashwa kolayini wokuqala kwesinye isikhathi akusebenzi nhlobo futhi kubizwa ngokuthi ukumelana nemithi. Kulokhu, uma impilo yonke yesiguli inhle, isiguli singazuza ekwelashweni ngezinye izidakamizwa. Ucwaningo olukhulu lwamanje lomdlavuza wepancreatic lugxile kakhulu ekwakhiweni kweminye imishanguzo yokwelashwa komugqa wesibili, kanye nemithi yokwelashwa yomugqa wesithathu neminye imishanguzo yokwelapha, eminye yayo ekhombise ithemba elikhulu.
Ukwelashwa okungajwayelekile
Non-standard treatment means that the drug used is not an indication for FDA approved treatment, which means that the FDA has not approved the drug for pancreatic cancer treatment, which is different from the drug’s instructions for use. For example, if your doctor wants to use drugs approved only for breast cancer to treat pancreatic cancer. At present, doctors recommend it only when there is substantial evidence that the drug may be effective for another disease. This evidence may include previously published studies, promising results from ongoing studies, or tumor genetic testing results suggesting that the drug may work.
Imiphumela emibi ye-Chemotherapy
The side effects of chemotherapy depend on which drugs patients receive, and not all patients have the same side effects. Side effects may include loss of appetite, nausea, vomiting, diarrhea, gastrointestinal problems, aphthous ulcers, and hair loss. People who receive chemotherapy are also more likely to have white blood cells, red blood cells, and thrombocytopenia due to chemotherapy, and are prone to infection, blood stasis, and bleeding.
Izidakamizwa ezithile ezisetshenziselwa umdlavuza we-pancreatic nazo zihlotshaniswa nemiphumela emibi ethile. Isibonelo, i-capecitabine ingadala ububomvu nokungakhululeki ezintendeni nasematheni ezinyawo. Lesi simo sibizwa nge-hand-foot syndrome. I-Oxaliplatin ingadala ukuba ndikindiki nokushosholozela eminweni nasezinzwaneni, futhi ibizwa nge-peripheral neuropathy. I-peripheral neuropathy nayo ingumphumela wecala we-paclitaxel. Le miphumela emibi ivame ukunyamalala phakathi kokulashwa nangemva kokuphela kokwelashwa, kepha ezinye izimpawu zingahlala isikhathi eside futhi zibe zimbi kakhulu njengoba ukwelashwa kuqhubeka.
Qonda ulwazi oluyisisekelo lwe-chemotherapy futhi ulungiselele ukwelashwa. Izidakamizwa ezisetshenziselwa ukwelapha umdlavuza ziyahlolwa njalo. Ukukhuluma nodokotela wakho imvamisa kuyindlela engcono kakhulu yokuqonda umuthi obekelwe wona, inhloso yawo kanye nemiphumela yawo emibi engaba khona noma ukuxhumana neminye imithi. Funda kabanzi ngemithi yakho kadokotela ngokusebenzisa i-database yezidakamizwa engasesheka.
Imithi yokwelashwa ehlosiwe
Ukwelashwa okuhlosiwe ukwelashwa kohlobo oluthile lomdlavuza, amaprotheni noma izindawo zezicubu ezinomthelela ekukhuleni komdlavuza nasekusindeni. Lokhu kwelashwa kungavimbela ukukhula nokusabalala kwamangqamuzana omdlavuza, ngenkathi kunciphisa ukulimala kwamaseli aphilile.
Recent studies have shown that not all tumors have the same target. To find the most effective treatment, your doctor may perform a tumor genetic test to determine the genes, proteins, and other factors in the tumor. This helps doctors better find the most effective treatment for each patient.
Erlotinib is approved by the FDA for use in combination with gemcitabine in the treatment of patients with advanced pancreatic cancer. Erlotinib can block the role of epidermal growth factor receptor (EGFR), an abnormal protein that helps the growth and spread of cancer. Side effects of erlotinib include acne rashes.
Ukwelashwa komdlavuza we-pancreatic we-metastatic
If the cancer spreads from its primary site to another part of the body, doctors call it metastatic cancer. If this happens, it is a good idea to talk to a doctor with experience in treatment. Different doctors can have different opinions on the best standard treatment plan. In addition, participation in clinical trials may be an option.
Uhlelo lokwelashwa komdlavuza we-pancreatic we-metastatic lungafaka inhlanganisela yezindlela zokwelapha ezingenhla, futhi uhlelo lokwelashwa luxhomeke kakhulu empilweni jikelele yesiguli kanye nalokho okuthandayo.
Ukwelashwa komugqa wokuqala kufaka:
Ukuhlanganiswa kwe-chemotherapy ne-fluorouracil, i-leucovorin, i-irinotecan ne-oxaliplatin kubizwa nge-FOLFIRINOX.
I-Gemcitabine plus paclitaxel isetshenziswa njengokwelashwa kolayini wokuqala noma ukwelashwa kolayini wesibili kweziguli ezithole i-FOLFIRINOX.
Ukwelashwa kolayini wesibili kufaka phakathi izindlela ezilandelayo. Lezi zivame ukusetshenziswa ezigulini ezinesifo esikhulayo noma ezinemiphumela emibi ngesikhathi sokwelashwa komugqa wokuqala.
Ezigulini esezitholile i-gemcitabine ne-paclitaxel, inhlanganisela ye-fluorouracil kanye ne-irinotecan noma i-oxaliplatin yinto engakhethwa. Ezigulini ezinesimo somzimba
I-ns ayikwazi ukwamukela imishanguzo eminingi, i-capecitabine inketho enemiphumela emibi embalwa.
Ezigulini esezitholile i-FOLFIRINOX, uhlobo lwemithi equkethe i-gemcitabine, njenge-gemcitabine iyodwa noma ihlanganiswe ne-paclitaxel, iyindlela efanelekayo.
Umdlavuza wePancreatic: ucwaningo
Odokotela basebenza kanzima ukufunda kabanzi mayelana nokwelashwa komdlavuza we-pancreatic, ukuthi ungawuvikela kanjani umdlavuza we-pancreatic, ukuthi ungawelashwa kanjani ngempumelelo, nokuthi ungazinakekela kanjani iziguli ngendlela engcono kakhulu.
Ucwaningo lwezakhi zofuzo kanye namangqamuzana
Emdlavuzeni, izakhi zofuzo ezilimele noma ezingajwayelekile zingadala ukukhula kwamaseli okungalawulwa. Inqubekela phambili eminingi yocwaningo isuselwa ekuhlonzeni izakhi zofuzo ezilimele kanye namaprotheni, ukuzilungisa noma ukuzishintsha ukwelapha umdlavuza we-pancreatic.
Izindlela ezahlukahlukene zamangqamuzana (njengokulandelana kwe-DNA kanye nokuhlaziywa kokuguquka kwezakhi zofuzo) manje zingasetshenziswa ukuhlaziya amasampuli wesimila se-pancreatic ukubheka izinguquko zofuzo. Lokhu kuhlaziywa manje kungenziwa ngisho nakwisampula yegazi ngoba ubuchwepheshe obusha buvumela ukuqoqwa nokuhlaziywa kwe-tumor DNA ekhona egazini. Odokotela bangathola imishanguzo emisha yokwelapha umdlavuza we-pancreatic ngokususelwa kulwazi lokuhlolwa kofuzo.
I-immunotherapy kumdlavuza we-pancreatic
Immunotherapy aims to enhance the body’s natural defense capabilities against cancer. It uses materials made by the body or laboratory to improve or restore the function of the immune system and target the treatment of pancreatic cancer.
An example of immunotherapy is a cancer vaccine, which can be made from a variety of sources, including pancreatic cancer cells, bacterial or human specific tumor cells. Many clinical trials have been completed or are in progress, attempting to use vaccines to treat various types of cancer, including pancreatic cancer. According to the patient’s condition, vaccine therapy can be given after chemotherapy, during chemotherapy or during alternative chemotherapy.
Another type of immunotherapy is a drug called an immune checkpoint inhibitor, which includes PD-1 and CTLA-4 antibodies. Immune checkpoint inhibitors have been approved for other types of cancer, such as melanoma and lung cancer, but are currently not suitable for pancreatic cancer. In general, these drugs are not very effective for pancreatic cancer. However, they may be suitable for a few pancreatic cancer patients with certain genetic mutations. The ongoing pancreatic cancer research is testing the combined effect of immune checkpoint inhibitors and chemotherapy or other new immunotherapy.
Ngaphezu kwalokho, abacwaningi bafunda izindlela zokuqoqa nokuguqula izakhi zofuzo ze-T, ezibizwa ngokuthi yi-adoptive immunotherapy.
Ukwelapha okuhlosiwe
I-Erlotinib okwamanje ivunyelwe ukwelashwa okuqondisiwe komdlavuza we-pancreatic futhi isetshenziswa ngokuhlanganiswa ne-gemcitabine. Ososayensi bacwaninga ngeminye imishanguzo engavimba ukukhula nokusabalala kwezimila eziyi-6 7 6 7, njengesidakamizwa esisodwa futhi njengengxenye yokwelashwa okuhlanganisiwe komdlavuza wepancreatic. Kodwa-ke, ezinye izindlela zokwelashwa ezihlosiwe, kufaka phakathi i-bevacizumab (Avastin) ne-cetuximab (i-Erbitux), aziboniswanga ukuthi zandisa impilo yeziguli ezinomdlavuza wepancreatic. Isakhi sofuzo esibizwa ngokuthi i-Ras sivame ukushintshwa kumdlavuza we-pancreatic. Abaphenyi banesithakazelo esikhulu kuRas, kepha ukwakhiwa kwezidakamizwa zalesi sakhi esithile kunzima kakhulu.
Ukwelashwa kwe-Gene kumdlavuza we-pancreatic
Ukwelashwa kwezakhi zofuzo ukulethwa kwezakhi zofuzo ezithile kumaseli omdlavuza, imvamisa aphathwa ngamagciwane aklanywe ngokukhethekile. Izakhi zofuzo ezijwayelekile ezilethwa enkabeni yamangqamuzana omdlavuza zifakwa ezakhiweni zofuzo ezisebenzayo zamangqamuzana omdlavuza njengoba amangqamuzana omdlavuza ehlukana, kususwa okungajwayelekile okunomthelela ekukhuleni komdlavuza. Izakhi zofuzo ezibangela ukuthi amangqamuzana omdlavuza afe.
Ukwelashwa ngamakhemikhali
Izinhlobo ezintsha nezinamandla ze-chemotherapy ejwayelekile zisacwaningwa. Isibonelo esisodwa yi-nanoliposome irinotecan, manje eseyamukelwe njengokwelashwa komugqa wesibili komdlavuza we-pancreatic osezingeni eliphezulu.
Amaseli esiqu somdlavuza
Amaseli esiqu somdlavuza wepancreatic amangqamuzana angahle amelane nomdlavuza. Ucwaningo lwamanje lugxile ekutholeni izidakamizwa ezingakhomba ngqo amaseli we-cancer stem.
